Bluedop Medical Secures £152.2k to Advance Cuffless Vascular Assessment Technology

London-based medical equipment manufacturer Bluedop Medical Ltd has secured an estimated £152.2k in a new funding round, bringing its estimated post-money valuation to £8.8m. The allotment of shares was completed on 19 March 2026, with the official filing registered today, 23 March 2026.

Incorporated in July 2014, Bluedop Medical develops a non-invasive ultrasound device designed to measure blood flow and pressure for the screening of Peripheral Artery Disease. The company provides this diagnostic technology to healthcare professionals for the clinical assessment of patients with vascular conditions.

The core problem Bluedop Medical addresses is the inefficiency and discomfort associated with traditional vascular screening methods. Historically, clinicians have relied on the Ankle Brachial Index to assess lower limb blood flow. Bluedop has developed a cuffless assessment technology that serves as an alternative to these traditional methods. The flagship product, BlueDop, aims to simplify lower limb diagnostics by offering rapid and reliable results without compromising patient comfort. The company states that its mission is to transform vascular health by making assessments more accessible, efficient, and pain-free, ultimately empowering clinicians with tools that improve patient outcomes.

Financially, the company is navigating the typical capital-intensive research and development phase associated with medical hardware. According to its latest accounts, Bluedop Medical reported a loss of £583,948. While official financial filings indicate a fractional employee count of 0.05, which typically reflects specific director payroll metrics rather than operational headcount, the company maintains a team of 11 employees according to its professional network presence. The London-headquartered firm lists its primary specialties as wound care, diabetic foot, vascular health, foot and ankle care, and tissue viability.

The £152.2k capital injection at an £8.8m valuation provides Bluedop Medical with additional resources to continue the commercialisation and refinement of its diagnostic tools. While specific investors were not named in the current filing, the valuation indicates sustained backing for the company's proprietary ultrasound technology.

This funding round fits into a broader narrative of sustained investment in the United Kingdom health technology sector. The UK government and the National Health Service have increasingly prioritised the adoption of innovative diagnostic tools to reduce clinical backlogs and improve patient care pathways. Initiatives such as the UK MedTech Funding Mandate and recent multimillion-pound funding packages from the Department of Health and Social Care underscore a national strategy to accelerate the uptake of cost-saving, efficiency-driving medical devices. Bluedop Medical operates directly within this critical intersection, providing hardware that streamlines the diagnostic process for vascular conditions and potentially reduces the long-term healthcare burdens associated with Peripheral Artery Disease.